Psychedelic Science 2026 — MAPS Conference
The world's largest psychedelic research conference returns. Three days of clinical data, policy discussions, and the future of psychedelic-assisted therapy.
About the Conference
Psychedelic Science, organized by the Multidisciplinary Association for Psychedelic Studies (MAPS), is the largest academic conference on psychedelic research in the world. The 2023 edition drew over 12,000 attendees. The 2026 conference focuses on "From Evidence to Access."
What to Expect
Research Presentations
- Phase 3 trial data for psilocybin in treatment-resistant depression
- Updated MDMA-assisted therapy results following FDA feedback
- Ketamine long-term outcomes and maintenance protocols
- Emerging data on DMT, ibogaine, and mescaline
Policy and Access
- State-level psychedelic therapy programs (Oregon, Colorado, emerging states)
- International regulatory pathways
- Equity and access in psychedelic medicine
- Indigenous knowledge and reciprocity frameworks
Clinical Practice
- Therapist training and competency standards
- Integration therapy best practices
- Managing challenging experiences
- Combining psychedelics with somatic and body-based therapies
Featured Speakers (Previous Years Have Included)
- Rick Doblin, PhD — MAPS Founder
- Robin Carhart-Harris, PhD — Imperial College / UCSF
- Matthew Johnson, PhD — Johns Hopkins
- Gül Dölen, MD PhD — UC Berkeley
- Natalie Gukasyan, MD — Johns Hopkins
Registration
| Tier | Price |
|---|---|
| Professional | $895 |
| Student / Early Career | $395 |
| Virtual attendance | $295 |
| Workshop add-ons | $150-$400 each |
Why This Conference Matters
Psychedelic Science is where the clinical data gets presented first. If you want to understand the actual evidence behind psychedelic-assisted therapy — not the hype, not the backlash, but the data — this is where it happens.
This is a curated listing. Body Mind State is not affiliated with MAPS or conference organizers.